Securities code: 002950 securities abbreviation: Allmed Medical Products Co.Ltd(002950) Announcement No.: 2022-002 Allmed Medical Products Co.Ltd(002950)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records and errors
Leading statements or material omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance: decline in the same direction
(1) Expected performance from January 1, 2021 to December 31, 2021
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 431990200 yuan – 464990200 yuan
Net profit of shareholders: 1157526600 yuan, down 59.83% – 62.68% over the same period of last year
Profit attributable to listed companies: 341990200-374490200 yuan
Deduction of non profit from shareholders: net profit of 106.11187 million yuan of recurring profit and loss
The profit decreased by 64.66% – 67.77% over the same period of last year
Basic earnings per share: 0.68 yuan / share – 0.73 yuan / share earnings: 1.83 yuan / share
Note: the basic earnings per share is calculated according to the latest share capital of 633265407 shares.
2、 Communication with accounting firms
This performance forecast has not been pre audited by the accounting firm and is the preliminary calculation result of the company.
3、 Explanation of performance change reasons
1. Affected by the epidemic situation in 2020, the price and quantity of the company’s infection protection products increased simultaneously, resulting in a significant increase in performance in 2020. Since 2021, the global epidemic prevention and control has entered the normalization stage, and the price and volume of infection protection products have returned to the normal level. Excluding epidemic related products, other businesses of the company have developed continuously and healthily.
2. Since 2021, except for the epidemic related businesses, the orders of other businesses of the company have increased. However, due to the lack of international shipping capacity, the delivery of some orders of the company has been delayed.
3. Since 2021, the company has continuously increased R & D investment and new product development.
4、 Other relevant instructions
This performance forecast is the preliminary calculation of the company’s financial department. The specific data will be disclosed in detail in the company’s 2021 annual report. Please pay attention to the investment risk.
It is hereby announced.
Allmed Medical Products Co.Ltd(002950) board of directors January 29, 2022
